Labopharm Once-Daily Tramadol Is “Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian firm may still have an opportunity to reach its end-of-2006 launch goal for the opioid analgesic.
You may also be interested in...
Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA
Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.
Biovail’s Tramadol ER Approved Without Additional Clinical Studies
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.
Purdue Signs On To Market Labopharm's Once-Daily Tramadol
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.